Latest News

Adults with obesity achieved up to 12.1% mean weight loss with oral ribupatide vs placebo in a 26-week phase 2 trial.

Gus Alva, MD, outlines challenges and opportunities, including stigma reduction, substance use counseling, and practical approaches that support patients.

Booster-backed speed-of-processing brain training links to lower Alzheimer disease and dementia diagnoses, suggesting modest computer exercises may delay decline.

Three-year BE HEARD data show bimekizumab sustains HS lesion clearance, cuts draining tunnels, and improves severity and quality of life.

FDA insulin updates, new obesity drug data, vaccine hesitancy strategies, and depression screening insights are featured in this week’s episode.

FDA clears a dissolvable sildenafil oral film for erectile dysfunction, offering discreet, water-free dosing and strong phase 3 results ahead of 2026 launch.

Researchers found that 58% of infants with atopic dermatitis achieved a 75% improvement in EASI-75 at week 4 with once-daily roflumilast cream 0.05%.

Physician researcher Fendrick offers an expert perspective on why removing cost barriers matters, and why navigation and patient realities still determine whether CRC screening succeeds.